MedTrace Logo

Post-Market Clinical Study of the PanOptix Intraocular Lens (IOL) in a Chinese Population

NCT04755231 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2023-10-10

Study results available
· View outcomes & findings →

Summary

The primary objective of this clinical study is to assess the clinical performance of the PanOptix IOL in a Chinese population.

Conditions

Interventions

DEVICE

AcrySof IQ PanOptix Presbyopia Correcting IOL

UV and blue-light filtering foldable multifocal IOL with a +2.17 diopter (D) addition power of intermediate visual acuity and a +3.25 D addition power of near visual acuity. This device is approved in China.

PROCEDURE

Cataract surgery

Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ PanOptix Presbyopia Correcting IOL

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Sr. Clinical Project Manager, Surgical · Alcon (China) Ophthalmic Product Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-19
Primary Completion
2022-08-31
Completion
2023-03-15
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04755231 on ClinicalTrials.gov